Multifaceted Activities of the Hiv-1 Transactivator of Transcription, Tat
KT Jeang,H Xiao,EK Rich
DOI: https://doi.org/10.1074/jbc.274.41.28837
IF: 5.485
1999-01-01
Journal of Biological Chemistry
Abstract:human immunodeficiency virus, type 1 long terminal repeat RNA polymerase II TATA-binding protein Tat-associated kinase carboxyl-terminal domain Tat-associated histone acetyltransferase TBP-associated factor Human immunodeficiency virus, type 1 (HIV-1)1 is the etiological agent for the acquired immunodeficiency syndrome (AIDS). HIV-1 is a retrovirus that encodes a small nuclear transcriptional activator protein, Tat (Fig. 1). In vivo, Tat is required for virus replication and is conserved in the genomes of all primate lentiviruses (1Myers G. Korber B.T. Foley B.T. Jeang K-T. Mellors J.W. Wain-Hobson S. Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM1996: III-11-III-26Google Scholar). Over the past decade, the transcriptional function(s) of Tat (reviewed in detail several years ago (2Jones K.A. Peterlin B.M. Annu. Rev. Biochem. 1994; 63: 717-743Crossref PubMed Scopus (559) Google Scholar)) has been intensely investigated. It has become clear that a primary role for Tat is in regulating productive and processive transcription from the HIV-1 long terminal repeat (LTR). Tat also has other activities; some are consistent with that of a secreted growth factor (3Chang H.K. Gallo R.C. Ensoli B.J. J. Biomed. Sci. 1995; 2: 189-202Crossref PubMed Scopus (91) Google Scholar, 4Trinh D.P. Brown K.M. Jeang K.T. Biochem. Biophys. Res. Commun. 1999; 256: 299-306Crossref PubMed Scopus (29) Google Scholar, 5Albini A. Ferrini S. Benelli R. Sforzini S. Giunciuglio D. Aluigi M.G. Proudfoot A.E. Alouani S. Wells T.N. Mariani G. Rabin R.L. Farber J.M. Noonan D.M. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 13153-13158Crossref PubMed Scopus (245) Google Scholar) and a potentiator of reverse transcription (6Harrich D. Ulich C. Garcia-Martinez L.F. Gaynor R. EMBO J. 1997; 16: 1224-1235Crossref PubMed Scopus (124) Google Scholar). Here we review recent insights into the multifaceted activities of Tat. Tat is a transcriptional activator that binds to a short nascent stem-bulge-loop leader RNA, TAR (trans-activation responsive (7Berkhout B. Silverman R.H. Jeang K.T. Cell. 1989; 59: 273-282Abstract Full Text PDF PubMed Scopus (513) Google Scholar, 8Dingwall C. Ernberg I. Gait M.J. Green S.M. Heaphy S. Karn J. Lowe A.D. Singh M. Skinner M.A. EMBO J. 1990; 9: 4145-4153Crossref PubMed Scopus (340) Google Scholar, 9Cordingley M.G. La Femina R.L. Callahan P.L. Condra J.H. Sardana V.V. Graham D.J. Nguyen T.M. Le Grow K. Gotlib L. Schlabach A.J. Colonno R.J. Proc. Natl. Acad. Sci. U. S. A. 1990; 87: 8985-8989Crossref PubMed Scopus (176) Google Scholar, 10Calnan B.J. Biancalana S. Hudson D. Frankel A.D. Genes Dev. 1991; 5: 201-210Crossref PubMed Scopus (292) Google Scholar)), for its activity. The 101-amino acid Tat protein, with residues 1–72 encoded by a first exon and residues 73–101 encoded by a second exon, can be arbitrarily considered as containing several “domains” (11Kuppuswamy M. Subramanian T. Srinivasan A. Chinnadurai G. Nucleic Acids Res. 1989; 17: 3551-3561Crossref PubMed Scopus (208) Google Scholar) (Fig. 1). Of interest, it should be noted that whereas an 86-amino acid form of Tat, which exists for a few laboratory-passaged virus strains (e.g. LAI, HXB2, pNL4–3) (Fig. 1), has been frequently used; this version represents a truncated and not naturally full-length protein. Indeed, a single nucleotide change in LAI, HXB2, and/or pNL4–3 at putative residue 87 unmasks in these respective genomes the conserved 101 amino acids (Fig. 1) of Tat that are found in most in vivo isolates of virus. This suggests that the premature termination codon that exists in laboratory isolates at position 87 conceivably arose artifactually during tissue culture passaging (12Neuveut C. Jeang K.T. J. Virol. 1996; 70: 5572-5581Crossref PubMed Google Scholar). Thus, that more than 90% of the more than 100 extant independently characterized HIV-1 Tat proteins maintain the 101 (and not the 86) amino acid configuration (1Myers G. Korber B.T. Foley B.T. Jeang K-T. Mellors J.W. Wain-Hobson S. Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM1996: III-11-III-26Google Scholar) is consistent with this interpretation. Hence, although residues 87–101 of Tat might not contribute greatly to the ex vivo propagation of HIV-1, their conservation in viruses that replicate in vivoprovides a good indication of their biological importance. In this regard, the second coding exon of Tat, which in many studies has been frequently not considered, has been shown to be significant in several biological assays (13Viglianti G. Mullins J.I. J. Virol. 1988; 62: 4523-4532Crossref PubMed Google Scholar, 14Tong-Starksen S. Baur A. Lu X.B. Peck E. Peterlin B.M. Virology. 1993; 195: 826-830Crossref PubMed Scopus (23) Google Scholar, 15Jeang K.-T. Berkhout B. Dropulic B. J. Biol. Chem. 1993; 268: 24940-24949Abstract Full Text PDF PubMed Google Scholar, 16Howcroft T.K. Strebel K. Martin M.A. Singer D.S. Science. 1993; 260: 1320-1323Crossref PubMed Scopus (200) Google Scholar, 17Verhoef K. Bauer M. Meyerhans A. Berkhout B. AIDS Res. Hum. Retroviruses. 1998; 14: 1553-1559Crossref PubMed Scopus (40) Google Scholar, 18Xiao H. Neuveut C. Benkirane M. Jeang K.T. Biochem. Biophys. Res. Commun. 1998; 244: 384-389Crossref PubMed Scopus (43) Google Scholar, 19Ott M. Emiliani S. Van Lint C. Herbein G. Lovett J. Chirmule N. McCloskey T. Pahwa S. Verdin E. Science. 1997; 275: 1481-1485Crossref PubMed Scopus (187) Google Scholar). Over the past decade, a detailed structure-function analysis of Tat has emerged, in part through the generation of an extensive collection of point mutants (Table I) produced from 11 laboratories (11Kuppuswamy M. Subramanian T. Srinivasan A. Chinnadurai G. Nucleic Acids Res. 1989; 17: 3551-3561Crossref PubMed Scopus (208) Google Scholar, 12Neuveut C. Jeang K.T. J. Virol. 1996; 70: 5572-5581Crossref PubMed Google Scholar, 20Garcia J.A. Harrich D. Pearson L. Misuyasu R. Gaynor R. EMBO J. 1988; 7: 3143-3147Crossref PubMed Scopus (139) Google Scholar, 21Sadaie M.R. Rappaport J. Benter T. Josephs S.F. Willis R. Wong-Staal F. Proc. Natl. Acad. Sci. U. S. A. 1988; 85: 9224-9228Crossref PubMed Scopus (62) Google Scholar, 22Ruben S. Perkins A. Purcell R. Joung K. Sia R. Burghoff R. Haseltine W.A. Rosen C.A. J. Virol. 1989; 63: 1-8Crossref PubMed Google Scholar, 23Hauber J. Malim M.H. Cullen B.R. J. Virol. 1989; 63: 1181-1187Crossref PubMed Google Scholar, 24Meyerhans A. Cheynier R. Albert J. Seth M. Kwok S. Sninsky J. Morfeldt-Manson L. Asjo B. Wain-Hobson S. Cell. 1989; 58: 901-910Abstract Full Text PDF PubMed Scopus (512) Google Scholar, 25Rice A.P. Carlotti F. J. Virol. 1990; 64: 1864-1868Crossref PubMed Google Scholar, 26Rice A.P. Carlotti F. J. Virol. 1990; 64: 6018-6026Crossref PubMed Google Scholar, 27Siderovski D.P. Matsuyama T. Frigerio E. Chui S. Min X. Erfle H. Sumner-Smith M. Barnett R.W. Mak T.W. Nucleic Acids Res. 1992; 20: 5311-5320Crossref PubMed Scopus (12) Google Scholar, 28Verhoef K. Berkhout B. J. Virol. 1999; 73: 2781-2789Crossref PubMed Google Scholar, 29Ulich C. Dunne A. Parry E. Hooker C.W. Gaynor R.B. Harrich D. J. Virol. 1999; 73: 2499-2508Crossref PubMed Google Scholar). From these mutants, one notes that single residue changes in domain 1 of Tat (amino acids 1–20) are well tolerated. By contrast, changes in six of the seven highly conserved cysteines in amino acids 21–40 (Fig. 1, domain2) abolish function (see Table I). Domain 3 (amino acids 41–48) contains a common RKGLGI motif found in HIV-1, HIV-2, and SIV Tat. Amino acids 1–48 together circumscribe a minimal activation domain for HIV-1 Tat (30Carroll R. Martarano L. Derse D. J. Virol. 1991; 65: 3460-3467Crossref PubMed Google Scholar, 31Derse D. Carvalho M. Carroll R. Peterlin B.M. J. Virol. 1991; 65: 7012-7015Crossref PubMed Google Scholar).Table IPoint mutations in TatAmino acid changesAmino acid changesFromaLetter(s) indicates original amino acid(s). Number indicates position of amino acid in Tat.TobLetter(s) indicates the resulting amino acid(s).Activitiesc++, >50% wild type; +, >10% wild type activity; +/− or −, ∼10% or <10% wild type activity.FromaLetter(s) indicates original amino acid(s). Number indicates position of amino acid in Tat.TobLetter(s) indicates the resulting amino acid(s).Activitiesc++, >50% wild type; +, >10% wild type activity; +/− or −, ∼10% or <10% wild type activity.Q2A++F32A+E2D5E9GGG(−)dMeasurement of contribution by Tat to reverse transcription (29).H33A−P3A++C34G−P3Q++C34S−P3L(+/−)dMeasurement of contribution by Tat to reverse transcription (29).G35A+V4A++C37G−D5A+C37S−D5N−eMeasurement is based not upon trans-activation of a reporter plasmid but on delayed replication of an HIV-1 molecular clone in T-cell lines (12, 28).F38A−P6A++F38L++P6S++F38R40LK−eMeasurement is based not upon trans-activation of a reporter plasmid but on delayed replication of an HIV-1 molecular clone in T-cell lines (12, 28).Δ3–6+K40D−P6P10LL++ (−)dMeasurement of contribution by Tat to reverse transcription (29).K40T++R7A++K41A−(+)dMeasurement of contribution by Tat to reverse transcription (29).L8A++K41fDifferent results reported for the same mutation from Refs.11 and 24.T−E9A++K41fDifferent results reported for the same mutation from Refs.11 and 24.T++P10A++L43F+P10P14LL++ (+/−)dMeasurement of contribution by Tat to reverse transcription (29).L43F−eMeasurement is based not upon trans-activation of a reporter plasmid but on delayed replication of an HIV-1 molecular clone in T-cell lines (12, 28).W11A++G44S++K12A++G44D−eMeasurement is based not upon trans-activation of a reporter plasmid but on delayed replication of an HIV-1 molecular clone in T-cell lines (12, 28).K12N++S46A++P18A++S46P−K19R++Y47H++A21D++Y47A++A21T23VA+G48S++T23A++G48R49gAmino acids beyond position 59 completely changed.SG++C22S−R49T++C22G−K50Stop−N23T++K50K51YY+N24A++K50K51SG+/(+/−)N24K++K50E++C25R−K50T++C25G−R52E++Y26A+R53I++Y26F++Q54N++C27S− (+)dMeasurement of contribution by Tat to reverse transcription (29).R55N+C27G−R55R56LT+K28K29AA+R56E++K28K29EA−R57Q63SE++C30G−L69I++C31S++Q72Stop+/−eMeasurement is based not upon trans-activation of a reporter plasmid but on delayed replication of an HIV-1 molecular clone in T-cell lines (12, 28).C31E−P81fshFrameshift of amino acids beyond position 81.+/−eMeasurement is based not upon trans-activation of a reporter plasmid but on delayed replication of an HIV-1 molecular clone in T-cell lines (12, 28).C31G++K90R+/−eMeasurement is based not upon trans-activation of a reporter plasmid but on delayed replication of an HIV-1 molecular clone in T-cell lines (12, 28).a Letter(s) indicates original amino acid(s). Number indicates position of amino acid in Tat.b Letter(s) indicates the resulting amino acid(s).c ++, >50% wild type; +, >10% wild type activity; +/− or −, ∼10% or <10% wild type activity.d Measurement of contribution by Tat to reverse transcription (29Ulich C. Dunne A. Parry E. Hooker C.W. Gaynor R.B. Harrich D. J. Virol. 1999; 73: 2499-2508Crossref PubMed Google Scholar).e Measurement is based not upon trans-activation of a reporter plasmid but on delayed replication of an HIV-1 molecular clone in T-cell lines (12Neuveut C. Jeang K.T. J. Virol. 1996; 70: 5572-5581Crossref PubMed Google Scholar, 28Verhoef K. Berkhout B. J. Virol. 1999; 73: 2781-2789Crossref PubMed Google Scholar).f Different results reported for the same mutation from Refs.11Kuppuswamy M. Subramanian T. Srinivasan A. Chinnadurai G. Nucleic Acids Res. 1989; 17: 3551-3561Crossref PubMed Scopus (208) Google Scholar and 24Meyerhans A. Cheynier R. Albert J. Seth M. Kwok S. Sninsky J. Morfeldt-Manson L. Asjo B. Wain-Hobson S. Cell. 1989; 58: 901-910Abstract Full Text PDF PubMed Scopus (512) Google Scholar.g Amino acids beyond position 59 completely changed.h Frameshift of amino acids beyond position 81. Open table in a new tab Perhaps the best studied region of Tat resides in amino acids 49–72 (domain 4), which contain a basic RKKRRQRRR motif. This peptide motif confers TAR RNA binding properties to Tat (32Dingwall C. Ernberg I. Gait M.J. Green S.M. Heaphy S. Karn J. Lowe A.D. Singh M. Skinner M.A. Vallerio R. Proc. Natl. Acad. Sci. U. S. A. 1989; 86: 6925-6929Crossref PubMed Scopus (402) Google Scholar, 33Roy S. Delling U. Chen C.-H. Rosen C.A. Sonenberg N. Genes Dev. 1990; 4: 1365-1373Crossref PubMed Scopus (326) Google Scholar, 34Weeks K.M. Crothers D.M. Cell. 1991; 66: 577-588Abstract Full Text PDF PubMed Scopus (302) Google Scholar, 35Chang Y.N. Jeang K.T. Nucleic Acids Res. 1992; 20: 5465-5472Crossref PubMed Scopus (31) Google Scholar) and is important for nuclear localization of the protein (22Ruben S. Perkins A. Purcell R. Joung K. Sia R. Burghoff R. Haseltine W.A. Rosen C.A. J. Virol. 1989; 63: 1-8Crossref PubMed Google Scholar, 23Hauber J. Malim M.H. Cullen B.R. J. Virol. 1989; 63: 1181-1187Crossref PubMed Google Scholar) and uptake of Tat by cells (3Chang H.K. Gallo R.C. Ensoli B.J. J. Biomed. Sci. 1995; 2: 189-202Crossref PubMed Scopus (91) Google Scholar). For association with TAR, the short basic motif contributes importantly to affinity but dictates insufficiently specificity of binding. Flanking amino acids outside this basic domain influence significantly the specificity of Tat-TAR interaction (36Churcher M.J. Lamont C. Hamy F. Dingwall C. Green S.M. Lowe A. Butler P.J.C. Gait M.J. Karn J. J. Mol. Biol. 1993; 230: 90-110Crossref PubMed Scopus (261) Google Scholar, 37Luo Y. Peterlin B.M. J. Virol. 1993; 67: 3441-3445Crossref PubMed Google Scholar). A recent detailed review of Tat-TAR RNA interaction is available elsewhere (38Rana T.M. Jeang K.-T. Arch. Biochem. Biophys. 1999; 365: 175-185Crossref PubMed Scopus (162) Google Scholar). Transcription from the HIV-1 LTR is several hundred-fold higher in the presence of Tat than in its absence. Thus, Tat must resolve a rate-limiting step at this promoter. Optimal Tat action requires, in addition to TAR RNA, basal (TATA and initiator sequence) and upstream promoter elements (i.e. Sp1) (39Berkhout B. Jeang K.T. J. Virol. 1992; 66: 139-149Crossref PubMed Google Scholar) (Fig.2). Recent experimental findings have added to our understanding of the mechanism(s) through which Tat acts through these elements. In considering Tat action, one understands that two operationally defined events occur for each round of transcription at virtually all promoters. These are: (i) recruitment of an RNA polymerase II (RNAP II) complex to the promoter and (ii) the escape of that complex from the promoter into productive elongation. A typicalrole proposed for transcriptional activator proteins is that of facilitating a rate-limiting step in the recruitment of TBP-bound RNAP II to the promoter (40Chatterjee S. Struhl K. Nature. 1995; 374: 820-822Crossref PubMed Scopus (167) Google Scholar, 41Xiao H. Friesen J.D. Lis J.T. Mol. Cell. Biol. 1995; 15: 5757-5761Crossref PubMed Scopus (102) Google Scholar). Although Tat is not a typical activator protein, it does possess the capacity to bind directly several general transcription factors including TFIID (42Kashanchi F. Piras G. Radonovich M.F. Duvall J.F. Roeder R. Brady J.N. Nature. 1994; 367: 295-299Crossref PubMed Scopus (229) Google Scholar), TFIIB (43Veschambre P. Roisin A. Jalinot P. J. Gen. Virol. 1997; 78: 2235-2245Crossref PubMed Scopus (27) Google Scholar), TFIIH (44Parada C.A. Roeder R.G. Nature. 1996; 384: 375-377Crossref PubMed Scopus (237) Google Scholar), and RNAP II (45Wu-Baer F. Sigman D. Gaynor R.B. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 7153-7157Crossref PubMed Scopus (60) Google Scholar). Thus, an attractively simple mechanism of how Tat might accelerate the rate of transcription from the HIV-1 LTR would be if it increased the recruitment of TBP/RNAP II to the viral promoter. This hypothesis was directly examined; and in such a study, it was found that Tat unlikely functions at recruiting TBP/RNAP II to the LTR promoter. Indeed, the rate-limiting event(s) resolved by Tat occurs at a step(s) post-TBP recruitment to the HIV-1 TATAA promoter (46Xiao H. Lis J.T. Jeang K.T. Mol. Cell. Biol. 1997; 17: 6898-6905Crossref PubMed Scopus (52) Google Scholar). What might be the “post-recruitment” step(s) influenced by Tat? Events that ensue after the docking of TBP/RNAP II at the promoter range, among others, from the consummation of a competent initiation complex to the clearance of such a complex from the promoter to the transit of cleared RNAP IIs into productive elongation. Because Tat function requires the presynthesis of at least the first 44 nascent nucleotides of TAR RNA (7Berkhout B. Silverman R.H. Jeang K.T. Cell. 1989; 59: 273-282Abstract Full Text PDF PubMed Scopus (513) Google Scholar), activation cannot occur until the initiated RNAP II has proceeded beyond this position (47Jeang K.-T. Berkhout B. J. Biol. Chem. 1992; 267: 17891-17899Abstract Full Text PDF PubMed Google Scholar). This scenario, which is very much compatible with Tat overcoming a “block” to transcription (44Parada C.A. Roeder R.G. Nature. 1996; 384: 375-377Crossref PubMed Scopus (237) Google Scholar, 48Marciniak R.A. Calnan B.J. Frankel A.D. Sharp P.A. Cell. 1990; 63: 791-802Abstract Full Text PDF PubMed Scopus (195) Google Scholar, 49Zhou Q. Sharp P.A. Science. 1996; 274: 605-609Crossref PubMed Scopus (140) Google Scholar) at a point after nucleotide +44, suggests that Tat might interact with factors that regulate the processivity of RNAP II elongation. General control of early RNAP II elongation at eukaryotic promoters is dictated by the actions of the negative (N-TEF) and positive (P-TEF) transcription elongation factor (50Marshall N.F. Price D.H. Mol. Cell. Biol. 1992; 12: 2078-2090Crossref PubMed Scopus (242) Google Scholar). A recent breakthrough in understanding Tat function came with the integration of positive transcription elongation factor, P-TEFb, into HIV-1 LTR-directed transcription. This recognition culminated from several preceding observations. First, it was found that a Tat-associated kinase (TAK (51Herrmann C.H. Rice A.P. J. Virol. 1995; 69: 1612-1620Crossref PubMed Google Scholar)) could phosphorylate the carboxyl-terminal domain (CTD) of the large subunit of RNAP II. Next, phosphorylation of the RNAP II-CTD was correlated with Tat activation of transcription (52Chun R.F. Jeang K.T. J. Biol. Chem. 1996; 271: 27888-27894Abstract Full Text Full Text PDF PubMed Scopus (94) Google Scholar, 53Okamoto O. Sheline C.T. Corden J.L. Jones K.A. Peterlin B.M. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 11575-11579Crossref PubMed Scopus (90) Google Scholar). Subsequently, TAK was elucidated to be the P-TEFb complex of proteins, which included the cyclin-dependent kinase, cdk9 (54Zhu Y. Pe'ery T. Peng J. Ramanathan Y. Marshall N. Marshall T. Amendt B. Mathews M.B. Price D.H. Genes Dev. 1997; 11: 2622-2632Crossref PubMed Scopus (613) Google Scholar, 55Mancebo H.S. Lee G. Flygare J. Tomassini J. Lu P. Zhu Y. Peng J. Blau C. Hazuda D. Price D. Flores O. Genes Dev. 1997; 11: 2633-2644Crossref PubMed Scopus (480) Google Scholar, 56Yang X. Gold M.O. Tang D.N. Lewis D.E. Aguilar-Cordova E. Rice A.P. Herrmann C.H. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 12331-12336Crossref PubMed Scopus (168) Google Scholar, 57Zhou Q. Chen D. Pierstorff E. Luo K. EMBO J. 1998; 17: 3681-3691Crossref PubMed Scopus (182) Google Scholar). In the P-TEFb complex, cdk9 was shown to be bound to one of several forms of cyclin T (T1, T2a, T2b (58Wei P. Garber M.E. Fang S.-M. Fischer W.H. Jones K.A. Cell. 1998; 92: 451-462Abstract Full Text Full Text PDF PubMed Scopus (1055) Google Scholar, 59Peng J. Zhu Y. Milton J.T. Price D.H. Genes Dev. 1998; 12: 755-762Crossref PubMed Scopus (452) Google Scholar)). The cdk9-cyclin T complex (P-TEFb) was found to associate directly with Tat. This association with P-TEFb facilitates a high affinity binding of Tat for TAR RNA (57Zhou Q. Chen D. Pierstorff E. Luo K. EMBO J. 1998; 17: 3681-3691Crossref PubMed Scopus (182) Google Scholar, 58Wei P. Garber M.E. Fang S.-M. Fischer W.H. Jones K.A. Cell. 1998; 92: 451-462Abstract Full Text Full Text PDF PubMed Scopus (1055) Google Scholar). P-TEFb can also bind to a previously demonstrated Tat co-factor, Tat-SF1, resulting in its phosphorylation (57Zhou Q. Chen D. Pierstorff E. Luo K. EMBO J. 1998; 17: 3681-3691Crossref PubMed Scopus (182) Google Scholar). This phosphorylation of Tat-SF1 has been suggested as an additional contributory event to the role of P-TEFb in HIV-1 LTR transcription (57Zhou Q. Chen D. Pierstorff E. Luo K. EMBO J. 1998; 17: 3681-3691Crossref PubMed Scopus (182) Google Scholar). Schematically, a simplified view of Tat/P-TEFb/TAR/RNAP II interaction can be represented by the illustration in Fig. 2 A. Association of Tat and P-TEFb (TAK) with TAR leads to phosphorylation of the RNAP II-CTD. Phosphorylation of RNAP II-CTD renders otherwise non-processive RNAP IIs into productively elongating molecules (60O'Brien T. Hardin S. Greenleaf A. Lis J.T. Nature. 1994; 370: 75-77Crossref PubMed Scopus (286) Google Scholar,61Dahmus M.E. J. Biol. Chem. 1996; 271: 19009-19012Abstract Full Text Full Text PDF PubMed Scopus (464) Google Scholar). If P-TEFb explains Tat transactivation, then are there roles to be played by other Tat-associated cellular factors (49Zhou Q. Sharp P.A. Science. 1996; 274: 605-609Crossref PubMed Scopus (140) Google Scholar, 62Nelbock P. Dillon P.J. Perkins A. Rosen C.A. Science. 1990; 248: 1650-1653Crossref PubMed Scopus (197) Google Scholar, 63Xiao H. Tao Y. Greenblatt J. Roeder R.G. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 2146-2151Crossref PubMed Scopus (70) Google Scholar, 64Sune C. Hayashi T. Liu Y. Lane W.S. Young R.A. Garcia-Blanco M.A. Mol. Cell. Biol. 1997; 17: 6029-6039Crossref PubMed Scopus (83) Google Scholar, 65Marshall N.F. Dahmus G.K. Dahmus M.E. J. Biol. Chem. 1998; 273: 31726-31730Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar, 66Chen D. Zhou Q. Mol. Cell. Biol. 1999; 19: 2863-2871Crossref PubMed Scopus (43) Google Scholar, 67Jeang K.T. Chun R. Lin N.H. Gatignol A. Glabe C.G. Fan H. J. Virol. 1993; 67: 6224-6233Crossref PubMed Google Scholar, 68McMillan N.A. Chun R.F. Siderovski D.P. Galabru J. Toone W.M. Samuel C.E. Mak T.W. Hovanessian A.G. Jeang K.T. Williams B.R. Virology. 1995; 213: 413-424Crossref PubMed Scopus (145) Google Scholar)? In considering this question, one notes that although the requirement for presynthesized TAR RNA is consistent with a Tat effect on RNAP II elongation, it is equally compatible with a mechanism affecting reinitiation of transcription (Fig. 2 B). Intracellularly, the ability to achieve continuous and rapid reinitiations, rather than simple initiations, represents the major determinant of the strength (defined by the amount of transcripts produced over time) of a eukaryotic promoter (69Yean D. Gralla J.D. Nucleic Acids Res. 1999; 27: 831-838Crossref PubMed Scopus (31) Google Scholar). Hence, although extant cell-free transcription studies (70Kato H. Sumimoto H. Pognonec P. Chen C.H. Rosen C.A. Roeder R.G. Genes Dev. 1992; 4: 655-666Crossref Scopus (157) Google Scholar, 71Keen N.J. Gait M.J. Karn J. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 2505-2511Crossref PubMed Scopus (91) Google Scholar, 72Li X.Y. Green M.R. Genes Dev. 1998; 12: 2992-2996Crossref PubMed Scopus (61) Google Scholar, 73Blair E.D. Roberts C.M. Clark-Lewis I. J. Biomed. Sci. 1995; 2: 136-145PubMed Google Scholar, 74Ping Y.H Rana T.M. J. Biol. Chem. 1999; 274: 7399-7404Abstract Full Text Full Text PDF PubMed Scopus (85) Google Scholar) have analyzed well the effect of Tat on the processivity of initiated polymerases, they do not address potential contributions to reinitiations. If Tat does contribute significantly to reinitiations, this could possibly explain the rather large discrepancies in the magnitudes measured for its cell-free elongation effects (reported variously as inductions of 3-fold (75Keen N.J. Churcher M.J. Karn J. EMBO J. 1997; 16: 5250-5272Crossref Scopus (61) Google Scholar) to 10-fold (54Zhu Y. Pe'ery T. Peng J. Ramanathan Y. Marshall N. Marshall T. Amendt B. Mathews M.B. Price D.H. Genes Dev. 1997; 11: 2622-2632Crossref PubMed Scopus (613) Google Scholar)) versus its intracellular effect on steady state transcription, which has been quantified as several hundred-fold. Indeed, recent biochemical evidence that Tat can exist in a TAR-RNA independent complex at the promoter (76Garcia-Martinez L.F. Ivanov D. Gaynor R.B. J. Biol. Chem. 1997; 272: 6951-6958Abstract Full Text Full Text PDF PubMed Scopus (48) Google Scholar, 77Liu Y. Sune C. Garcia-Blanco M.A. Virology. 1999; 255: 337-346Crossref PubMed Scopus (11) Google Scholar) and findings that this TAR-independent complex may directly contact DNA-bound Sp1 (78Cujec T.P. Cho H. Maldonado E. Meyer J. Reinberg D. Peterlin B.M. Mol. Cell. Biol. 1997; 7: 1817-1823Crossref Scopus (108) Google Scholar, 79Chun R.F. Semmes O.J. Neuveut C. Jeang K.T. J. Virol. 1998; 72: 2615-2629Crossref PubMed Google Scholar) suggest that some Tat moieties might not necessarily be tethered to an elongating RNAP II and migrate away from the promoter (71Keen N.J. Gait M.J. Karn J. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 2505-2511Crossref PubMed Scopus (91) Google Scholar, 75Keen N.J. Churcher M.J. Karn J. EMBO J. 1997; 16: 5250-5272Crossref Scopus (61) Google Scholar). In principle, TAR-RNA independent protein-protein contact of Tat with Sp1 (67Jeang K.T. Chun R. Lin N.H. Gatignol A. Glabe C.G. Fan H. J. Virol. 1993; 67: 6224-6233Crossref PubMed Google Scholar, 79Chun R.F. Semmes O.J. Neuveut C. Jeang K.T. J. Virol. 1998; 72: 2615-2629Crossref PubMed Google Scholar) implies that some Tat protein could be stably docked at a promoter proximal locale. If so, promoter-associated Tat (Fig.2 C) could influence transcriptional reinitiations in a fashion similar to promoter-bound TBPs/TAFs/TFIIA (80Zawel L. Reinberg D. Annu. Rev. Biochem. 1995; 64: 533-561Crossref PubMed Scopus (391) Google Scholar). It remains to be directly tested whether such a mechanistic function could exist for Tat. HIV-1 has an additional transcriptional complexity that is not found for non-integrating viruses. For large portions of its life cycle, HIV-1, like other retroviruses, exists as chromosomally integrated proviral DNA (81Verdin E. Paras P. Van Lint C. EMBO J. 1993; 12: 3249-3259Crossref PubMed Scopus (414) Google Scholar) in infected cells. In its integrated form, the HIV-1 LTR is bound with histone proteins in a nucleosomally organized format. In this regard, access by RNAP II to these histone-packaged LTRs is a step that is not well reflected by the existing cell-free transcription assays for Tat function. Four recent reports, however, have addressed this issue from an intracellular context. Collectively, these reports firmly demonstrate a role for a Tat-associate histone acetyltransferase (TAH) in transcriptional access of RNAP II to integrated proviral LTRs. TAH activity was shown to be redundantly provided by the p300/CBP, PCAF, and/or TAF250 (82Hottiger M.O. Nabel G.J. J. Virol. 1998; 72: 8252-8256Crossref PubMed Google Scholar, 83Benkirane M. Chun R.F. Xiao H. Ogryzko V.V. Howard B.H. Nakatani Y. Jeang K.T. J. Biol. Chem. 1998; 273: 24898-24905Abstract Full Text Full Text PDF PubMed Scopus (253) Google Scholar, 84Marzio G. Tyagi M. Gutierrez M.I. Giacca M. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 13519-13524Crossref PubMed Scopus (266) Google Scholar, 85Weissman J.D. Brown J.A Howcroft T.K. Hwang J. Chawla A. Roche P.A. Schiltz L. Nakatani Y. Singer D.S. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 11601-11606Crossref PubMed Scopus (136) Google Scholar) proteins. Large viruses, such as those from the herpes family, have genome sizes of 200 or more kilobase pairs. By contrast, the HIV-1 genome is less than one-twentieth in size. For purposes of viral replication, the smaller HIV-1 genome must provide functions similar to those encoded within the genomes of larger viruses. A possible consequence of genome size constraint is that each HIV-1 open reading frame might have been selected to evolve multiple functions. Indeed, based on genetic inferences, Tat was shown to have activities in addition to its transcriptional function for the viral LTR (86Huang L.M. Joshi A. Willey R. Orenstein J. Jeang K.T. EMBO J. 1994; 13: 2886-2896Crossref PubMed Scopus (86) Google Scholar). Some of these additional functions have been described from several independent laboratories and include the activation of quiescent T-lymphocytes (19Ott M. Emiliani S. Van Lint C. Herbein G. Lovett J. Chirmule N. McCloskey T. Pahwa S. Verdin E. Science. 1997; 275: 1481-1485Crossref PubMed Scopus (187) Google Scholar), the induction of cellular apoptosis (87Li C.J. Friedman D.J. Wang C. Metelev V. Pardee A.B. Science. 1995; 268: 429-431Crossref PubMed Scopus (549) Google Scholar), and the modulation of cellular gene expression such as that for manganese-dependent superoxide dismutase (88Westendorp M.O. Shatrov V.A. Schulze-Osthoff K. Frank R. Kraft M. Los M. Krammer P.H. Droge W. Lehmann V. EMBO J. 1995; 14: 546-554Crossref PubMed Scopus (367) Google Scholar). Tat also has functions consistent with an extracellular chemokine (5Albini A. Ferrini S. Benelli R. Sforzini S. Giunciuglio D. Aluigi M.G. Proudfoot A.E. Alouani S. Wells T.N. Mariani G. Rabin R.L. Farber J.M. Noonan D.M. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 13153-13158Crossref PubMed Scopus (245) Google Scholar) and/or growth factor (4Trinh D.P. Brown K.M. Jeang K.T. Biochem. Biophys. Res. Commun. 1999; 256: 299-306Crossref PubMed Scopus (29) Google Scholar). There is evidence that Tat might additionally affect gene expression through post-transcriptional (18Xiao H. Neuveut C. Benkirane M. Jeang K.T. Biochem. Biophys. Res. Commun. 1998; 244: 384-389Crossref PubMed Scopus (43) Google Scholar) and/or reverse transcription (20Garcia J.A. Harrich D. Pearson L. Misuyasu R. Gaynor R. EMBO J. 1988; 7: 3143-3147Crossref PubMed Scopus (139) Google Scholar) steps. Many of these non-transcriptional activities for Tat have not been studied in sufficient detail; their physiological relevance remains to be verified in future investigations. Studies on Tat over the last decade have yielded important biological and virological insights. Early work established Tat as a lead example of an RNA-binding protein that functions in eukaryotic transcription. Later, in studying the transcriptional activity of Tat, new understandings of general controls of transcriptional elongation and processivity and activation of chromosomally integrated promoters were gained. From the latter arena we have learned how this RNA-binding protein can cooperate with RNAP II CTD kinases and histone acetylases in modulating expression from the LTR promoter. In studies unrelated to transcription, Tat has provided an important paradigm for how highly charged proteins can be specifically taken up into cells (89Vocero-Akbani A.M. Heyden N.V. Lissy N.A. Ratner L. Dowdy S.F. Nat. Med. 1999; 5: 29-33Crossref PubMed Scopus (222) Google Scholar); and in aspects related to AIDS pathogenesis, there is emerging evidence that HIV-1 virulence (90Péloponèse Jr., J.M. Yves Collette Y. Grégoire C. Bailly C. Campèse D. Meurs E.F. Olive D. Loret E.P. J. Biol. Chem. 1999; 274: 11473-11478Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar) and a potentially useful approach for a viral vaccine (91Goldstein G. Nat. Med. 1996; 2: 960-964Crossref PubMed Scopus (145) Google Scholar) are impacted by the biological functions of the Tat protein. Indeed, although we have elucidated much of the transcriptional properties of Tat, much more remains to be learned.